{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:06:27Z","timestamp":1792796787104,"version":"4.5.0"},"reference-count":28,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":79,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 AG072946"],"award-info":[{"award-number":["P30 AG072946"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["A&amp;D Transl Res &amp; Clin Interv"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The advent of disease\u2010modifying therapies for Alzheimer's disease (AD) has raised many questions and debates in the field as to the clinical benefits, risks, and costs of such therapies. The controversies have resulted in the perception that many clinicians are apprehensive about prescribing these medications to their patient populations. There also remains widespread uncertainty as to the economic impact, cost benefit ratio, and safety oversight for use of these medications in standard clinical care settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To contextualize such issues, the present study compared anti\u2010amyloid biologic therapy (lecanemab) to four commonly used biologic agents in other fields, including trastuzumab for breast cancer, bevacizumab for lung cancer, etanercept for rheumatoid arthritis, and ocrelizumab for multiple sclerosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The data presented demonstrate comparable costs, clinical benefits, and risks for these biologic agents in their disparate disease states.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These results provide context for the costs, clinical benefits, and safety regarding the mainstream use of anti\u2010amyloid biologic agents for the prevention of cognitive loss. While the era of disease\u2010modifying therapies for AD is now in its infancy, there is an expectation that these discoveries will be followed by improved therapies and combination treatments leading to greater efficacy in ameliorating the clinical trajectory of AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Anti\u2010amyloid therapy costs are comparable to other commonly used biologics.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Anti\u2010amyloid therapy efficacy is comparable to other commonly used biologics.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Anti\u2010amyloid therapy safety is compatible with other commonly used biologics.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/trc2.12500","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T07:00:57Z","timestamp":1726642857000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Perspectives on the clinical use of anti\u2010amyloid therapy for the treatment of Alzheimer's disease: Insights from the fields of cancer, rheumatology, and neurology"],"prefix":"10.1002","volume":"10","author":[{"given":"Gregory A.","family":"Jicha","sequence":"first","affiliation":[{"name":"Departments of Internal Medicine, Neurology and Pathology University of Kentucky College of Medicine  Lexington Kentucky USA"},{"name":"The Markey Cancer Center, and the Sanders\u2010Brown Center on Aging University of Kentucky  Lexington Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin L.","family":"Abner","sequence":"additional","affiliation":[{"name":"The Markey Cancer Center, and the Sanders\u2010Brown Center on Aging University of Kentucky  Lexington Kentucky USA"},{"name":"Department of Epidemiology and Environmental Health University of Kentucky College of Public Health  Lexington Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif P.","family":"Coskun","sequence":"additional","affiliation":[{"name":"Departments of Internal Medicine, Neurology and Pathology University of Kentucky College of Medicine  Lexington Kentucky USA"},{"name":"The Markey Cancer Center, and the Sanders\u2010Brown Center on Aging University of Kentucky  Lexington Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Huffmyer","sequence":"additional","affiliation":[{"name":"Departments of Internal Medicine, Neurology and Pathology University of Kentucky College of Medicine  Lexington Kentucky USA"},{"name":"College of Pharmacy University of Kentucky  Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Tucker","sequence":"additional","affiliation":[{"name":"The Markey Cancer Center, and the Sanders\u2010Brown Center on Aging University of Kentucky  Lexington Kentucky USA"},{"name":"Department of Epidemiology and Environmental Health University of Kentucky College of Public Health  Lexington Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter T.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Departments of Internal Medicine, Neurology and Pathology University of Kentucky College of Medicine  Lexington Kentucky USA"},{"name":"The Markey Cancer Center, and the Sanders\u2010Brown Center on Aging University of Kentucky  Lexington Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,9,18]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261\u2010023\u201001331\u20101"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.123"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12388"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259\u2010023\u201000633\u20102"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.adj9255"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12385"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13016"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912\u2010023\u201001478\u20102"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.12.040"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221130501"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt\u20102017\u20100155"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.85"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2022.100737"},{"key":"e_1_2_8_15_1","unstructured":"Review IfCaE.Treatment Options for Advanced Non\u2010Small Cell Lung Cancer: Effectiveness Value and ValueBased Price Bench.https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/MWCEPAC_NSCLC_Final_Evidence_Report_Meeting_Summary_110116.pdf"},{"key":"e_1_2_8_16_1","doi-asserted-by":"crossref","unstructured":"Review IfCaE.Disease\u2010Modifying Therapies for RelapsingRemitting and Primary\u2010Progressive Multiple Sclerosis: Effectiveness and Value. doi:10.18553\/jmcp.2023.29.7.857","DOI":"10.18553\/jmcp.2023.29.7.857"},{"key":"e_1_2_8_17_1","unstructured":"Review IfCaE.Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value.https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_Final_Scoping_Document_050919.pdf"},{"key":"e_1_2_8_18_1","unstructured":"Review IfE.Lecanemab for Early Alzheimer's Disease: Final Policy Recommendations. doi:10.18553\/jcmp.2023.29.9.1078"},{"key":"e_1_2_8_19_1","unstructured":"Genentech. Herceptin (trastuzumab) [package insert].U.S. Food and Drug Administration. Revised June 2024. Accessed August 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/103792s5354lbl.pdf"},{"key":"e_1_2_8_20_1","unstructured":"Genentech. Avastin (bevacizumab) [package insert].U.S. Food and Drug Administration. Revised September 2024. Accessed August 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125085s340lbl.pdf"},{"key":"e_1_2_8_21_1","unstructured":"Enbrel (etanercept) [package insert].U.S. Food and Drud Administration. Revised July 2024. Accessed August 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/103795s5597s5598s5599lbl.pdf"},{"key":"e_1_2_8_22_1","unstructured":"Genentech. Ocrevus (ocrelizumab) [package insert].U.S. Food and Drug Administration. Revised June 2024. Accessed August 2024.https:\/\/accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761053s035lbl.pdf"},{"key":"e_1_2_8_23_1","unstructured":"Eisai Inc. Leqembi (lecanemab\u2010irmb) [package insert].U.S. Food and Drug Administration. Revised July 2024. Accessed August 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761269Orig1s001lbl.pdf"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp\u20102023\u2010331941"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq786"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756\u20109966\u201029\u201058"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/0018578717731733"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/03009740701607067"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"}],"container-title":["Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/trc2.12500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:45:05Z","timestamp":1761493505000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/trc2.12500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1002\/trc2.12500"],"URL":"https:\/\/doi.org\/10.1002\/trc2.12500","archive":["Portico"],"relation":{},"ISSN":["2352-8737","2352-8737"],"issn-type":[{"value":"2352-8737","type":"print"},{"value":"2352-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"2024-04-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e12500"}}